Related Experiment Video
Updated: Mar 10, 2026
05:25
Author Spotlight: Evaluating Therapeutic Strategies to Enhance Liver Regeneration
Published on: May 24, 2024
3.8K
Metabolic Syndrome After Liver Transplantation: Five-Year Prevalence and Risk Factors
F García-Pajares1, I Peñas-Herrero1, R Sánchez-Ocaña1
1Gastroenterology Service, Liver Transplantation Unit, Valladolid, Spain.
Transplantation Proceedings
|December 10, 2016
Summary
Metabolic syndrome (MS) affects 38.2% of liver transplant recipients 5 years post-surgery. Obesity and diabetes, both before and after transplantation, are key risk factors for developing MS.
Area of Science:
- Hepatology and Transplant Medicine
- Metabolic and Cardiovascular Research
Background:
- Orthotopic liver transplantation (OLT) survival rates have improved, increasing focus on post-transplant metabolic complications.
- Metabolic syndrome (MS) significantly contributes to morbidity and mortality in OLT patients.
Purpose of the Study:
- To determine the prevalence of metabolic syndrome (MS) and its components in OLT patients.
- To identify factors associated with MS development after OLT.
Main Methods:
- Retrospective analysis of 204 OLT patients with at least 1-year follow-up.
- Diagnosis of MS using modified National Cholesterol Education Program-Adult Treatment Panel-III (NCEP-ATP III) criteria.
- Logistic regression analysis to identify independent predictors of MS.
Main Results:
- MS was diagnosed in 38.2% of patients at 5 years post-OLT.
- Pre-transplantation and 1-year post-transplantation obesity and diabetes were significant predictors of MS.
- Hypertriglyceridemia and hypertension at 1 year post-transplantation were also associated with MS.
Conclusions:
- The prevalence of MS in OLT patients at our center is comparable to published data.
- Obesity and diabetes are critical risk factors for MS development in the pre- and post-transplantation periods.
- Targeting these factors may help mitigate metabolic complications in OLT survivors.
Related Concept Videos
01:24Overview of Lipid Metabolism
6.3K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
6.3K
01:28Kidney Transplant I: Introduction
624
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
624
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
340
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
340
01:26Kidney Transplant II: Surgical Procedure
628
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
628
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
259
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
259
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
246
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
246